Comment on “The efficacy of zuranolone versus placebo in postpartum depression and major depressive disorder: a systematic review and meta-analysis”
International Journal of Clinical Pharmacy · 2024
DOI: 10.1007/s11096-024-01763-5 ↗Kurz gefasst
Leserbrief in der Zeitschrift International Journal of Clinical Pharmacy, 2024. Verfasst von Kazumasa Kotake. Beteiligte Einrichtung: Department of Pharmacy, Zikei Hospital/Zikei Institute of Psychiatry, 100-2 Urayasu Honmachi, Minami-Ku, Okayama-shi, Okayama, 702-8508, Japan. kotta…. Hauptthemen laut MEDLINE: Depression, Postpartum, Major Depressive Disorder. Die Arbeit nennt 3 Literaturangaben.
Themen: Depression
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Zikei Hospital/Zikei Institute of Psychiatry, 100-2 Urayasu Honmachi, Minami-Ku, Okayama-shi, Okayama, 702-8508, Japan. kottanketty@gmail.com.
Zitieren
APA
Kotake, K. (2024). Comment on “The efficacy of zuranolone versus placebo in postpartum depression and major depressive disorder: a systematic review and meta-analysis”. International Journal of Clinical Pharmacy. https://doi.org/10.1007/s11096-024-01763-5
Vancouver
Kotake K. Comment on “The efficacy of zuranolone versus placebo in postpartum depression and major depressive disorder: a systematic review and meta-analysis”. International Journal of Clinical Pharmacy. 2024. doi:10.1007/s11096-024-01763-5
BibTeX
@article{Kotake2024,
author = {Kotake, Kazumasa},
title = {Comment on “The efficacy of zuranolone versus placebo in postpartum depression and major depressive disorder: a systematic review and meta-analysis”},
journal = {International Journal of Clinical Pharmacy},
year = {2024},
doi = {10.1007/s11096-024-01763-5}
}
EUVIMED